I agree that this site is using cookies. You can find further informations here.
X
Luis Manso
846  results:
Search for persons X
?
1

Atezolizumab plus bevacizumab and chemotherapy for metastat..:

Oaknin, Ana ; Gladieff, Laurence ; Martínez-García, Jerónimo...
The Lancet.  403 (2024)  10421 - p. 31-43 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Predictive World Models for Social Navigation:

, In: Advances in Intelligent Systems and Computing; Advances in Computational Intelligence Systems,
Oguzie, Goodluck ; Ekart, Aniko ; Manso, Luis J. - p. 53-64 , 2024
Link: https://doi.org/10.1007/..
 
?
3

Everolimus plus endocrine therapy beyond CDK4/6 inhibitors ..:

Sánchez-Bayona, Rodrigo ; Lopez de Sa, Alfonso ; Jerez Gilarranz, Yolanda...
Breast Cancer Research and Treatment.  206 (2024)  3 - p. 551-559 , 2024
Link: https://doi.org/10.1007/..
 
?
4

Multi-person 3D pose estimation from unlabelled data:

Rodriguez-Criado, Daniel ; Bachiller-Burgos, Pilar ; Vogiatzis, George.
Machine Vision and Applications.  35 (2024)  3 - p. , 2024
Link: https://doi.org/10.1007/..
 
?
5

Safety of bevacizumab and olaparib as frontline maintenance..:

Romero, Ignacio ; Guerra, Eva ; Madariaga, Ainhoa.
Frontiers in Oncology.  13 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
6

Atezolizumab and chemotherapy for advanced or recurrent end..:

Colombo, Nicoletta ; Biagioli, Elena ; Harano, Kenichi...
The Lancet Oncology.  , 2024
Link: https://doi.org/10.1016/..
 
?
7

Digging into phenotype change in mismatch repair deficient ..:

Rey-Cárdenas, Macarena ; Parrilla-Rubio, Lucia ; Manso, Luis...
Gynecologic Oncology Reports.  49 (2023)  - p. 101278 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A G..:

Yubero, Alfonso ; Estévez, Purificación ; Barquín, Aránzazu...
Gynecologic Oncology Reports.  48 (2023)  - p. 101211 , 2023
Link: https://doi.org/10.1016/..
 
?
9

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indicati..:

Mouron, Silvana ; Bueno, Maria J ; Muñoz, Manuel...
JNCI Cancer Spectrum.  7 (2023)  2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
10

Real-world safety and effectiveness of maintenance nirapari..:

Cueva, Juan F. ; Palacio, Isabel ; Churruca, Cristina...
European Journal of Cancer.  182 (2023)  - p. 3-14 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Distribution of PD-L1, TROP2 and HER2- "lowness" in early t..:

Bueno, Maria Jose ; Mouron, Silvana ; Caleiras, Eduardo...
Clinical and Translational Oncology.  26 (2023)  5 - p. 1273-1279 , 2023
Link: https://doi.org/10.1007/..
 
?
12

Cost-effectiveness of olaparib plus bevacizumab versus beva..:

Cedillo, Sergio ; Garí, Carla ; Aceituno, Susana...
International Journal of Gynecologic Cancer.  34 (2023)  2 - p. 277-284 , 2023
Link: https://doi.org/10.1136/..
 
?
13

Self-supervised Monocular Depth Estimation: Let's Talk Abou..:

, In: 2023 IEEE/CVF International Conference on Computer Vision (ICCV),
Saunders, Kieran ; Vogiatzis, George ; Manso, Luis J. - p. 8873-8883 , 2023
Link: https://doi.org/10.1109/..
 
?
14

SocNavGym: A Reinforcement Learning Gym for Social Navigati..:

, In: 2023 32nd IEEE International Conference on Robot and Human Interactive Communication (RO-MAN),
Kapoor, Aditya ; Swamy, Sushant ; Bachiller, Pilar. - p. 2010-2017 , 2023
Link: https://doi.org/10.1109/..
 
?
15

Updated progression-free survival and final overall surviva..:

Lorusso, Domenica ; Mouret-Reynier, Marie-Ange ; Harter, Philipp...
International Journal of Gynecologic Cancer.  34 (2023)  4 - p. 550-558 , 2023
Link: https://doi.org/10.1136/..
 
1-15